EUCTR2011-004287-30-HR进行中（未招募）1 期
A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency
Alexion Pharmaceuitcals Inc0 个研究点目标入组 31 人开始时间: 2014年9月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Subject will be > 8 months of age at the time of dosing.
- •2.Subject or subject’s parent or legal guardian (if applicable) consents to participation in the study. If the subject is of minor age, he/she is willing to provide assent where required per local regulations, and if deemed able to do so.
- •3.Confirmation of LAL Deficiency diagnosis as determined by the central lab; a subject who received a liver or hematopoietic stem cell transplant who does not show evidence of LAL enzyme deficiency by DBS due to the effects of transplantation must have either:
- •a.Molecular genetic testing which confirms mutations in both alleles of the LIPA gene; OR
- •b.Appropriately documented (based on consultation with the Sponsor) historical result of an enzyme test prior to hematopoietic or liver transplantation
- •4. Subjects > 8 months but < 4 years of age at Screening will have at least 1 of the following documented clinical manifestations of LAL Deficiency:
- •a.Dyslipidemia (defined as Screening low-density lipoprotein cholesterol (LDL-C) > 130 mg/dL; triglycerides (TG) > 200 mg/dL);
- •b.Elevated transaminases (ALT =1.5x ULN);
- •c.Impaired growth as defined as:
- •i.WFA or SFA less than the age- and gender- appropriate 5th percentile on a standard World Health Organization (WHO) (subjects = 24 months of age) or Centers for Disease Control and Prevention (CDC) (subjects > 24 months and < 4 years of age) WFA or SFA chart for at least 3 months prior to study entry; OR
- •ii.Poor weight gain as evidenced by calculated weight percentile decreasing across 2 major percentile (99th, 97th, 95th, 90th, 75th, 50th, 25th, 10th, 5th, 3rd, and 1st) lines on a standard WHO (subjects =24 months of age) or CDC (subjects > 24 months and <4 years of age) WFA chart over a period of 6 months prior to study entry;
- •d.Suspected malabsorption with:
- •i.Persistent unexplained gastrointestinal symptoms such as nausea, diarrhea, abdominal pain, and bloating; OR
- •ii.Unexplained anemia, or other abnormalities suggestive of malabsorption; AND
- •iii.Documented small intestinal disease involvement on a small bowel biopsy performed within 1 year of Screening
- •e.Other clinical manifestation of LAL Deficiency in the opinion of the investigator and in consultation with the Sponsor.
- •5.Subjects = 4 years of age at Screening will have at least 1 of the following documented clinical manifestations of LAL Deficiency:
- •a. Evidence of advanced liver disease at Screening accompanied by:
- •i.Clinically significant portal hypertension as defined by a hepatic venous pressure gradient (HVPG) greater than or equal to 10 mmHg; OR
- •ii.Documented esophageal varices at Screening
- •b.Disease recurrence in subjects with past liver or hematopoietic transplants
- •c.Persistent dyslipidemia (defined as LDL-C > 130mg/dL, TG > 200mg/dL, or high-density lipoprotein cholesterol (HDL C) <40mg/dL in males, and < 50mg/dL in females) that has persisted despite 3 or more months of treatment with one or more lipid-lowering therapies such as statins, cholesterol absorption inhibitors (ezetimibe), combination therapies (single-pill; ezetimibe/simvastatin, niacin/simvastatin), fibrates (fenofibrate, gemfibroz
排除标准
- •1.Subject meets eligibility criteria for another interventional study of sebelipase alfa in LAL Deficiency that is open for enrollment in the region where the subject will receive treatment.
- •2.Subject has known causes of active liver disease other than LAL Deficiency which have not been adequately treated (e.g., chronic viral hepatitis, autoimmune hepatitis, alcoholic liver disease).
- •3.Subject is unable or unwilling to comply with study procedures.
- •4.Subject received a hematopoietic stem cell or liver transplant < 2 years from the time of dosing.
- •5.Females who are nursing or pregnant.
- •6.Subject with co-morbidities other than complications due to LAL Deficiency which, in the opinion of the Investigator and in consultation with the Sponsor, are irreversible or associated with a high mortality risk within 6 months, or would interfere with study compliance or data interpretation (e.g. excessive alcohol consumption).
- •7.Exposure to any investigational product within 30 days of Screening for a small molecule and 60 days of Screening for a biologic.
- •8.Known hypersensitivity to eggs.
研究者
相似试验
进行中（未招募）
1 期
Study of sebelipase alfa in a broad population of patients with Lysosomal Acid Lipase Deficiency (LALD).ysosomal Acid Lipase Deficiency (LALD)MedDRA version: 19.1Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850EUCTR2011-004287-30-DEAlexion Pharmaceuitcals Inc30
已完成
2 期
A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase deficiencyNL-OMON43955Alexion Pharmaceuticals Inc1
进行中（未招募）
1 期
Study of sebelipase alfa in a broad population of patients with Lysosomal Acid Lipase Deficiency (LALD).ysosomal Acid Lipase Deficiency (LALD)MedDRA version: 16.1Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850EUCTR2011-004287-30-ESSynageva BioPharma Corp.20
进行中（未招募）
1 期
Study of sebelipase alfa in a broad population of patients with Lysosomal Acid Lipase Deficiency (LALD).EUCTR2011-004287-30-ITSynageva BioPharma Corp.20
进行中（未招募）
1 期
Study of sebelipase alfa in a broad population of patients with Lysosomal Acid Lipase Deficiency (LALD).ysosomal Acid Lipase Deficiency (LALD)MedDRA version: 19.1Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850EUCTR2011-004287-30-DKAlexion Pharmaceuticals inc20